Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

By Seema Hakhu Kachru Houston, Aug 28 () In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine. According to BCM, Hyderabad-headquartered BE has licenced the recombinant protein COVID-19 vaccine candidate developed at Baylor. The company engaged in licence negotiations with the <keyword id="9839857" type="COMPANY" weightage="20" keywordseo="bcm-ventures">BCM Ventures</keyword> team after initial discussions on Baylor's technology and how it could possibly inform a vaccine to address the current global pandemic. The company will leverage its past experience for the further development and commercialisation of the vaccine candidate, which is currently produced using a proven yeast-based expression technology, the Texas-based BCM said. "Recent information that India has become the third-leading nation in terms of COVID-19 cases has sparked concern that COVID-19 will become widespread and a serious and deadly infection across the crowded urban areas of South Asia," said Dr Peter Hotez, professor and dean of <keyword id="9839858" type="COMPANY" weightage="20" keywordseo="the-national-school-of-tropical-medicine">the National School of Tropical Medicine</keyword> at Baylor, at a webinar organised by the Consul General of India in Houston, Aseem Mahajan, last week. India has recorded 33,87,500 coronavirus cases and 61,529 fatalities due to the disease, while the US is leading the chart with over 5,869,000 cases and 180,800 deaths. "The healthcare sector is predicted to grow steadily in India and the US. Given the complementarities, companies in both the countries have a great opportunity to build synergies including to partner together for global supply chains, joint research and manufacturing," Mahajan told . Hotez and his colleagues have already been making SARs and MERS vaccines. "Then, when we got word about COVID-19, we saw that the sequence for the new virus was similar to some of the viruses that we were already making vaccines for," said Hotez, who is also the co-director of Texas Children's Centre for Vaccine Development. Hotez and his team were able to quickly move on to creating a COVID-19 vaccine, which resulted in the collaboration with a large vaccine producer in India. "They have the capacity to make a billion doses of the vaccine that we've developed at Baylor College of Medicine. "We're very worried that a lot of the low and middle income countries will be kind of pushed aside if we only rely on the Operation Warp Speed vaccines so we think what we do at Texas Children's and Baylor should fill that critically important gap," he said. The vaccine is still in trials in India with the hope that it will be able to roll out sometime next year. "For the past two decades, our vaccine centre has been advancing global health vaccines to prevent neglected and emerging diseases," said associate dean Dr Maria Elena Bottazzi. "We are therefore well suited to embark on this important collaboration with BE and look forward to facilitating the technology transfer for the COVID-19 vaccine to India and for the world. The current focus is on transfer of the technology for BE to initiate scale-up of the manufacturing process and undertake further development of the vaccine candidate," she said. Meanwhile, the BE in a statement said the partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low- and middle-income nations. "If the vaccine development is successful, we expect to make several hundred million doses of the vaccine available annually," said Narender Dev Mantena, director of <keyword id="9752060" type="COMPANY" weightage="20" keywordseo="BioE-Holdings-Inc">BioE Holdings Inc</keyword>, who heads BE's novel vaccine initiative.

US company ties-up with India's BE for COVID-19 vaccine production

Hyderabad, Dec 8 (IANS) Biological E. Ltd, a Hyderabad-based vaccine and pharmaceutical company, and the Ohio State Innovation Foundation on Tuesday announced an exclusive license agreement for a Covid-19 vaccine technology. The Ohio State Innovation Foundation has licensed novel live attenuated measles virus vectored vaccine candidates against SARS-CoV-2, which were developed by the Ohio State University College of Veterinary Medicine, exclusively to Biological E. BE will be responsible for the evaluation and further development, including the commercialisation of the vaccine candidates. "Translating this vaccine platform into the hands of a global vaccine company for further evaluation and development is a critical step and we are excited that Biological E has taken on this role," said Dr Patrick Green, Associate Dean for Research and Graduate Studies, Ohio State University College of Veterinary Medicine. The Ohio college team's approach utilises the SARS-CoV-2 spike protein as a target protein for SARS-CoV-2 vaccine candidates, generating a series of attenuated recombinant measles viruses (rMeVs) expressing SARS-CoV-2 antigens. All resultant rMeVs, the basis for the vaccine candidates, grow to high virus titer in Vero cells, a WHO-approved cell line for vaccine production. They were also shown to express the recombinant S antigens, a critical step in developing a SARS-CoV-2 vaccine. The rMeV-based SARs-CoV-2 vaccine candidates have proceeded through proof-of-concept trials in multiple animal models - demonstrating successful production of SARS-CoV-2 antibodies. "BE has been working to develop a safe and effective vaccine for the COVID-19. BE is very happy to help further this innovation and expand that effort," said Mahima Datla, Managing Director, Biological E. "With this licensing transaction, we have expanded the repertoire of the candidate vaccine(s) that we are evaluating, both in terms of the antigen and the platform technology," said Narender Dev Mantena, Director, BioE Holdings Inc., who heads BE's novel vaccine initiative. --IANS ms/vd

Biological E gets license for Ohio varsity's Covid vaccine candidate

Hyderabad, Biological E. Ltd, a Hyderabad-based vaccine and <keyword id="24214" type="COMPANY" weightage="20" keywordseo="pharmaceutical-company">pharmaceutical company</keyword>, and <keyword id="10398356" type="COMPANY" weightage="20" keywordseo="the-ohio-state-innovation-foundation">the Ohio State Innovation Foundation</keyword> on Tuesday announced an exclusive license agreement for a Covid-19 vaccine technology. The <keyword id="15091" type="LOCATION" weightage="20" keywordseo="Ohio">Ohio</keyword> State Innovation Foundation has licensed novel live attenuated measles virus vectored vaccine candidates against SARS-CoV-2, which were developed by the <keyword id="10398357" type="UNKNOWN" weightage="20" keywordseo="ohio-state-university-college">Ohio State University College</keyword> of Veterinary Medicine, exclusively to Biological E. BE will be responsible for the evaluation and further development, including the commercialisation of the vaccine candidates. "Translating this vaccine platform into the hands of a global vaccine company for further evaluation and development is a critical step and we are excited that Biological E has taken on this role," said Dr Patrick Green, Associate Dean for Research and Graduate Studies, <keyword id="123150" type="COMPANY" weightage="20" keywordseo="Ohio-State-University">Ohio State University</keyword> College of Veterinary Medicine. The Ohio college team's approach utilises the SARS-CoV-2 spike protein as a target protein for SARS-CoV-2 vaccine candidates, generating a series of attenuated recombinant measles viruses (rMeVs) expressing SARS-CoV-2 antigens. All resultant rMeVs, the basis for the vaccine candidates, grow to high virus titer in Vero cells, a WHO-approved cell line for vaccine production. They were also shown to express the recombinant S antigens, a critical step in developing a SARS-CoV-2 vaccine. The rMeV-based SARs-CoV-2 vaccine candidates have proceeded through proof-of-concept trials in multiple animal models - demonstrating successful production of SARS-CoV-2 antibodies. "BE has been working to develop a safe and effective vaccine for the COVID-19. BE is very happy to help further this innovation and expand that effort," said Mahima Datla, Managing Director, Biological E. "With this licensing transaction, we have expanded the repertoire of the candidate vaccine(s) that we are evaluating, both in terms of the antigen and the platform technology," said Narender Dev Mantena, Director, BioE Holdings Inc., who heads BE's novel vaccine initiative. SEE ALSO: <a href="https://www.businessinsider.in/business/telecom/news/mukesh-ambani-says-jio-will-rollout-5g-services-by-june-2021-and-it-will-go-beyond-india/articleshow/79619222.cms">Mukesh Ambani says Jio will rollout 5G services by June 2021 – and it will go beyond India</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-canara-bank-sun-pharma-titan-nbcc-gujarat-state-fertilizers-coffee-day-and-others/articleshow/79617464.cms">Top stocks to watch — Canara Bank, Sun Pharma, Titan, NBCC, Gujarat State Fertilizers, Coffee Day, and others</a>

You Searched For "BioE Holdings Inc" and got 3 results

US company ties-up with India's BE for COVID-19 vaccine production

PTI

Biological E gets license for Ohio varsity's Covid vaccine candidate

IANS

Biological E gets license for Ohio varsity's COVID-19 vaccine technology

IANS

Popular Keywords

Buying Guides